Managing Risk with Third Parties and Strategic Partners State Law Compliance The Overview November 8, 2007 Pharmaceutical Regulatory and Compliance Congress.

Slides:



Advertisements
Similar presentations
4.02 Compliance Training Brian A. Dahl Senior Counsel Takeda Pharmaceuticals North America, Inc. November 14, 2003.
Advertisements

Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
PwC Medical Device Compliance Survey Discussion of Survey Results.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Short-term: support populations most effected by trafficking trafficking Long-term: change societal norms and create sustainable options that increase.
Copyright Eastern PA EMS Council February 2003 Health Information Portability and Accountability Act It’s the law.
Changes to HIPAA (as they pertain to records management) Health Information Technology for Economic Clinical Health Act (HITECH) – federal regulation included.
COMPLYING WITH HIPAA PRIVACY RULES Presented by: Larry Grudzien, Attorney at Law.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
Sales & Marketing Compliance Training
ELECTION AND QUALIFICATIONS OF DIRECTORS Robert D. Strahota, Assistant Director * SEC Office of International Affairs Prepared for the panel on Improving.
Security Controls – What Works
WELCOME Annual Meeting & Compliance Seminar. Code of Conduct - Impact on Corporate Culture by Andy Greenstein Knight Capital Group, Inc.
WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October Washington, D.C. David Davidovic,
BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA California Transparency in Supply Chain Act, SB 657, Chapter 556, Statutes of 2010 David.
Minnesota Law and Health Information Exchange Oversight Activities James I. Golden, PhD State Government Health IT Coordinator Director, Health Policy.
Promoting Objectivity in Research by Managing, Reducing, or Eliminating Conflicts of Interest UT HOP UT HOP The University of Texas at Austin.
Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,
Vendor Risk: Effective Management is Essential
© Huron Consulting Group Inc. All Rights Reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Network Security Policy Anna Nash MBA 737. Agenda Overview Goals Components Success Factors Common Barriers Importance Questions.
Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.
HIPAA PRIVACY AND SECURITY AWARENESS.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
0 Overview of the Foreign Corrupt Practices Act and Related Corporate Procedures (A312, A312A and A301)
How to Develop Internal Monitoring Programs SEVENTH ANNUAL PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Stephen F. Mohr Global.
The Management of Service centers NCURA REGIONS VI and VII CONFERENCE April 7, 2009.
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
1 Today’s Presentation Sarbanes Oxley and Financial Reporting An NSTAR Perspective.
Best Practices: Financial Resource Management February 2011.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress How to establish a Compliance Program that will Minimize the Impact of.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
PwC 21 CFR Part 11 – A Risk Management Perspective Patrick D. Roche 07 March 2003, Washington D.C.
© Huron Consulting Services LLC. All rights reserved. Aggregate Spend 101 March 5, 2009 L I F E S C I E N C E S A D V I S O R Y S E R V I C E S Manny Tzavlakis.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Pre-Conference Questions: Legal/Regulatory & Operational Considerations March 5, 2009.
FleetBoston Financial HIPAA Privacy Compliance Agnes Bundy Scanlan Managing Director and Chief Privacy Officer FleetBoston Financial.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Gift Disclosure and Registration Tom Tremble, AdvaMed Julie Cohen, AdvaMed.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
DGS Recommendations to the Governor’s Task Force on Contracting & Procurement Review Report Overview August 12, 2002.
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Special Program for Internal/Compliance Audit Professionals: Enterprise Risk.
Agenda for Session Compliance in Clinical Research
Standard Unique Health Identifier for Health Care Providers April 9, th Annual HIPAA Summit Gail Kocher Highmark.
Session 1.01 US Healthcare Professionals Abroad – Issues and Practical Solutions Caroline West – Senior VP, Chief Compliance and Risk Officer Shire Pharmaceuticals.
Compliance August 18, Agenda Outline Status Draft of Answers.
RECOMMENDATIONS OF THE GOVERNOR ’ S TASK FORCE ON CONTRACTING AND PROCUREMENT REVIEW Report Overview PD Customer Forum September 2002.
PwC National disclosure audio conference: Analysis of the revised Physician Payments Sunshine Act and state drug marketing laws February 10, 2009 “Where.
Flowers Hospital General Compliance Training-Students 2013.
California’s New Compliance Law Kelly N. Reeves
Building A Pharmaceutical Compliance Program Presentation to the Sixth Annual Congress on Health Care Compliance February 7, 2003 Janice Toran Fujisawa.
Connecting for Health Common Framework: the Model Contract for Health Information Exchange Gerry Hinkley com July 18, 2006 Davis Wright.
0 Due Diligence Monitoring and Auditing of Third Party Vendors October 28, 2008 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum.
AND CE-Prof, Inc. January 28, 2011 The Greater Chicago Dental Academy 1 Copyright CE-Prof, Inc
The Health Insurance Portability and Accountability Act of 1996 “HIPAA” Public Law
1 The Implementation of Fair Market Value What can we learn from recent enforcement actions? Debjit Ghosh Life Sciences Advisory Services Huron Consulting.
The Role of the HHS Office of Inspector General Summit on Disclosure, Transparency, and Aggregate Spend March 5, 2009 Mary E. Riordan, Office of Counsel.
The Latest in California Market Conduct
Affiliate Rules/Code of Conduct
Analysis of the Proposed Sunshine Rule: Legal Considerations
The Most Important Element to Assure That Your Sales and Marketing Compliance Program is Working Effectively: Monitoring and Auditing Kelly B. Freeman,
Risk Management: why and how to protect your health center
Analysis of the Proposed Sunshine Rule Implementation Issues
Presentation transcript:

Managing Risk with Third Parties and Strategic Partners State Law Compliance The Overview November 8, 2007 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Managing Risk with Third Parties and Strategic Partners Track Paul J. Silver Managing Director Huron Consulting Group

Managing Risk with Third Parties and Strategic Partners Track I.State Reporting Regulatory Landscape II.Who are “Third Party Vendors” and “Indirect Sources”? III.Compliance Risks Associated with Third Party Vendors a.Operational / business risks and considerations b.Data risks and considerations State Reporting Responsibilities: Manufacturer vs. Vendor IV.Risk Mitigation Considerations Agenda

Managing Risk with Third Parties and Strategic Partners Track State Reporting Regulatory Landscape Existing State Laws –Minnesota passed the first marketing disclosure law in Between 2001 and 2005, similar laws were enacted in California, Maine, Nevada, Vermont, West Virginia, and the District of Columbia. Proposed Federal Legislation: –“Physician Payments Sunshine Act of 2007” (S. 2029) –Will require companies with $100 million or more in annual gross revenues to report the name and address of the physician, any facility with which the physician is affiliated, the value and the date of the payment or gift, its purpose, and what, if anything, was received in exchange. Companies that fail to report the required information would be subject to penalties ranging from $10,000 to $100,000 for each violation. Pending State Legislation –In 2007, at least 14 states have pending bills that would require manufacturers to report to the state's health department gifts and other expenditures. –Familiarizing personnel early in the process will reduce the risk of non-compliance and training costs in the future

Managing Risk with Third Parties and Strategic Partners Track Pending Enacted NVNV Gift Disclosure Laws: ME, MN, VE, WV, and DC File a report identifying the value, nature, and purpose of any gift, fee, payment, subsidy, or any economic benefit greater than $25 Prohibition & Disclosure Law: MN Prohibits certain gifts over $50 to any one HCP per year Requires disclosure of compensation and reimbursements valued at more than $100 Comprehensive Compliance & Reporting Law: CA Establish annual, per-physician limits on gifts, promotional marketing materials and other items or activities Compliance with PhRMA Code and OIG Guidelines NV Adopt a written marketing code of conduct, a training program, identify a compliance officer, conduct annual audits of compliance with the company's marketing code, and adopt policies for investigating non- compliance with the marketing code Each state has taken its own unique approach to marketing disclosure and prohibition laws, while having various degrees of breadth and scope: State Reporting Regulatory Landscape

Managing Risk with Third Parties and Strategic Partners Track Penalties State Reporting Regulatory Landscape Potential injunctive relief, costs, and attorneys fees Media scrutiny Reputation / image defaming Physician Payments Sunshine Act of 2007 (S. 2029): A civil monetary violation not less than $10,000 but not more than $100,000 for each violation. StatePenalty DC A civil violation for which a fine of $1,000 plus costs and attorney's fees may be adjudged ME May be enforced in a civil action brought by the Attorney General. Failure to provide a report as required results in a civil violation of a $1,000 fine plus costs and attorney's fees. MN Any violators are considered guilty of a misdemeanor VT A civil penalty of not more than $10,000 per violation and injunctive relief, costs, and attorneys fees. Each unlawful failure to disclose constitutes as separate violation.

Managing Risk with Third Parties and Strategic Partners Track Payments are sometimes made to HCPs on behalf of the company through third party vendors and “indirect sources”. Depending upon whom the payment is made, the company may be liable for reporting such expenditures: Third-Party Vendor Payments –Event planners (e.g. speaker program/training, advisory boards, etc.) –Co-promotion arrangements / partners –Consultants Co-Promotional Program Reporting Responsibilities –Pharmaceutical / medical device manufacturers Payments by Other (Internal) Divisions –Parent company –Subsidiary –Sister/operating companies –Functional departments within the same organization Global Organization –Reimbursing US HCPs for international programs Who are Third Party Vendors & Indirect Sources?

Managing Risk with Third Parties and Strategic Partners Track Number of Third Party Vendors Within the Organization –Tracking the number of third party vendors being engaged among the brands and functional areas Detail of Payment Information Provided by Third Party Vendor –Every transaction must be identifiable and attributable to individual HCPs in order for aggregation, tracking, and reporting (aggregate spend) –Capturing information including: value, nature, and purpose of each transaction –Segregation of expenditures by HCP Potential Non-Compliance with Reporting and Tracking –Exceed spending limits –Inappropriate allocations –Inaccurate aggregation of spend for one particular HCP Operational / Business Risks and Considerations Compliance Risks Associated with Third-Party Vendors

Managing Risk with Third Parties and Strategic Partners Track Unique Identification of HCP Across Multiple Systems –Same name conundrum: (e.g. John Smith and John Smith Jr.) –Multiple addresses –Multiple group practice and affiliations –Multiple tax ID and other identifiers Capture and Identification of HCP Type –Physicians –Mid-Levels (NP, PA, RPh, etc.) –KOLs (non-prescribers) Orphan records –Varying versions of a name: (e.g. Robert Mayer MD vs. Rob Mayer) Data Risks and Considerations Compliance Risks Associated with Third-Party Vendors

Managing Risk with Third Parties and Strategic Partners Track Compliance with sales & marketing payment disclosure and spending limitation requires actions by both the manufacturer as well as the vendor: Manufacturer Responsibilities and Possible Risks: –Collecting and compiling required information –Approving payments –Review for hidden payments and expenses –Data security and protection of proprietary information –Record retention and documentation –Vendor training on organizational reporting obligations Third Party Vendor Responsibilities and Possible Risks: –Compliance with organization’s state reporting policies –Read and certify compliance with standard operating procedures –Provide information at the appropriate level of detail State Reporting Responsibilities: Manufacturer vs. Vendor

Managing Risk with Third Parties and Strategic Partners Track Risk Mitigation Considerations Standard Operating Procedures –Provide gift and business expenditure and state reporting SOPs to vendors –Request certification of receipt and comprehension of SOPs Education –Provide training to vendors regarding state reporting obligations Co-Promotion Contract Terms and Conditions –Clear definition of reporting responsibilities in contract terms Monitor and Audit –Inventory all agreements and services being provided by multiple vendors –Designate one individual within the company to oversee TPV processes (e.g. purchasing/procurement or contracting group) –Independent audit of third-party vendor contracts Standard Data Formats –Required data fields –Common data format Policies and Procedures –Standard policies and procedures for reporting and tracking payments made to HCPs by other divisions and/or the global organization Disciplinary Action for Non-Compliance –Policies for non-compliance with third party vendor

Managing Risk with Third Parties and Strategic Partners Track Questions? Paul J. Silver Managing Director Huron Consulting Group (678) Atlanta Office (646) New York Office

Managing Risk with Third Parties and Strategic Partners Operational Aspect of Managing Third Party Vendors November 8, 2007 Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Managing Risk with Third Parties and Strategic Partners Track Bill Fitzgerald Director Global Compliance Alcon Laboratories, Inc. Elizabeth Lewis Vice President Commercial Law Millennium Pharmaceuticals, Inc.

Managing Risk with Third Parties and Strategic Partners Track Defining Third Party Vendor Types  Event Planners (e.g. speaker program/training, advisory boards, etc.)  Co-promotion Arrangements / Partners  Consultants  Internal Vendors (e.g. global, business units, etc.)

Managing Risk with Third Parties and Strategic Partners Track Identification / Inventory of Third Party Vendors Across Organization  Business Inventory (sales, force, home office, MSLs, clinical, PR, etc.)  Data Inventory (systems, software, spreadsheets where data resides)

Managing Risk with Third Parties and Strategic Partners Track Collecting and Compiling Required Information  Development of standard data formats for third party vendors

Managing Risk with Third Parties and Strategic Partners Track State Reporting Data Management, Risks, & Considerations November 8, 2007 Bill Buzzeo Vice President & General Manager Cegedim Dendrite Compliance Solutions Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Managing Risk with Third Parties and Strategic Partners Track

Managing Risk with Third Parties and Strategic Partners Track Third Party Vendor Data

Managing Risk with Third Parties and Strategic Partners Track Data Submissions Secure access, authorization and authentication Process and automated business rules to insure all 3Ps are submitted Partner / Vendor management reporting

Managing Risk with Third Parties and Strategic Partners Track Level of Detail Transaction and summary level Dashboards Graphics for decision support

Managing Risk with Third Parties and Strategic Partners Track Data Completeness Customer Master Product Master Data enrichment

Managing Risk with Third Parties and Strategic Partners Track Data Accuracy Data cleansing Data validation Data warehousing

Managing Risk with Third Parties and Strategic Partners Track Data Formats Industry standards: XML, EDI, Microsoft Office documents Others?

Managing Risk with Third Parties and Strategic Partners Track Certifications / Compliance 21 CFR Part 11 ISO 9000 CMM ITIL IEEE

Managing Risk with Third Parties and Strategic Partners Track Rights to Data Intellectual Property Public knowledge Trade Secrets Residual Rights for people that know longer work with this data